Prof. Dr. Serdar Turhal, lisans öncesi öğrenimlerinin ardından İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi'nde başladığı tıp eğitimini başarıyla tamamlayarak tıp doktoru unvanı almıştır. İhtisasını ise, Amerika Birleşik Devletlerinde Connecticut eyaletindeki Yale Üniversitesi’ne bağlı Griffin Hastanesi’nde 1993 yılında tamamlayarak Dahiliye - İç Hastalıkları uzmanı olmuştur. Ayrıca Mount Sinai Tıp Fakültesi Hematoloji – Onkoloji Bilim
Dalı Mount Sinai Tıp Fakültesi, New York, New York, ABD'de Tıbbi Onkoloji üzerine yan dal ihtisas eğitimini de tamamlamıştır.
Marmara Üniversite Hastanesi Onkoloji Bilim Dalı'nda öğretim üyesi olarak görev yapmış olan Prof. Dr. Serdar Turhal, mesleki çalışmalarına şu an İstanbul'da bulunan özel muayenehanesi'nde devam etmektedir.
Weight gain is a well-known and unwanted complication of adjuvant chemotherapy in breast cancer. We observed that the female Turkish cancer patients frequently gain weight with adjuvant treatment of breast cancer and planned to examine the magnitude of this problem in early breast cancer patients treated at our hospital. A total of 176 early breast…
Devamını Oku
treatment is surgery, with breast conserving surgery (BCS) being widely used for early-stage disease. Due to changes in body image, depressive symptoms can occur after surgery. Here, we evaluate factors that affect patients’ decision on surgery, and investigate differences in the level of depression after mastectomy or BCS in a population of Turkish patients. ……
Devamını Oku
Cancer care provided within home environment is usually provided by spouses, siblings, children, relatives, and friends of the cancer patients. These individuals play a substantial role in meeting the practical, emotional, and even nursing care needs of their relatives without being paid [1,2]. They are usually referred to as ‘informal caregivers’ [1]. Research shows that…
Devamını Oku
Gastrointestinal stromal tumour (GIST) is an extraordinary and interesting disease both to physicians and patients. Every patient with GIST is a new experience for the medical oncologist [1–5]. The Response Evaluation Criteria in Solid Tumors (RECIST) are used in GIST. However, RECIST criteria show limitations in the response evaluation in imatinibtreated GIST [6, 7]. We…
Devamını Oku